Capital circulates — plenty of it, by the numbers. But it doesn't reach the tissue that needs it. Working communities. Rural villages. The capillaries of the real economy. So the periphery starves while the central vessels clog and burst.
The lock between the bloodstream and the cell is broken. What’s missing isn’t more sugar in the blood — it’s a key that fits.
I’m a doctor. A weird one, but still a doctor. I trained in one of the best health systems in the world, with some of the most competent doctors — mentors who I still love and respect. And what they taught me about blood circulation, healing tissues, and restoring flow, I have applied to poverty, war, ecological destruction, and violence at a population scale.
Kapital is a very specific invention. Fernando Lezama and Jhony Lopez's financial coaching on how to pay impoverished Indigenous collectives properly, our “delinquent savants” activist fintech payment system backing it, funded by the World Bank, named by Nwki Flores, and automated.
Like the ancient story of the seven blind men and the elephant this problem has confounded a lot of people, who then argue. It turns out Kapital is just an odd shape, and everyone was right. But it’s the shape it is. It’s a magical realism guara. And if you don’t know what that means, then no problem — I gave you a picture.
But Kapital is just a weird beast.
Globally, it has proven to be an incredible solution. There is no shortage of capital. There is a shortage of perfusion — of capital actually reaching the cells doing the metabolic work. Indigenous communities. Smallholder farmers. The people producing food and keeping ecosystems alive. Diabetes is, at bottom, a disease of distribution, not supply. So is this.
Which is why, when people who were smart enough to see the scale started asking about who was going to be inflating the pricing of Kapital (specifically who was going to take attribution, data/learning rights, delivery ownership, and platform/success economics) we decided not to reinvent the wheel.
This problem has already been solved.
The synthesized key
We didn’t build Kapital to make a gazillion dollars. We built it to pay our partners fairly without controlling them.
Specifically in international development and climate markets, it solves the control paradox. The service layer solves the recipient problem. Partners that were so badly treated for so long by the financial system, they couldn’t even receive the money when it arrived, or had strongly negative emotional responses to positive money flows.
It’s a synthesized key in the lock of poverty. And there is a lock, a protocol, just like getting sugar into a cell. And it’s blocked right now. So the design fit the lock between the bloodstream and the cells that have been shut out of it in a very particular way.
Indigenous communities are like cells. They have a homeostasis, a controlled and regulated environment. And they have a protocol, a safety system for influences from outside. And when capital enters, specifically digital currencies, it needs to respect that homeostasis and regulatory mechanism.
So this design gets capital to the people the current system routes around — without corroding their culture if they have opted out of the system. And many Indigenous communities have never converted to a system designed to impoverish them. Or they have been excluded by cultural protocols that are corrosive to their internal balance or regulate against it in many ways, large and small.
We need to convert capital to Kapital, in other words.
When we got the key to the lock, we realized it was critical to use it properly. Savimbo never allows debt on the Kapital platform, for instance. We get traditional approval, and we put the traditional regulatory mechanism into the system. Then we introduce capital.
We’ve been debating the pricing internally for a long time. And the more we argued, the more the insulin analogy stopped being a metaphor and became a model. Diabetes is a comparatively simple disease. The ethics of treating it are well-worked. And insulin, specifically, comes with almost a century of hard-earned lessons about what happens when you get the pricing of essential infrastructure right — and what happens when you let it drift.
What insulin was supposed to be
In 1923, Frederick Banting, Charles Best, and James Collip were granted the US patent for insulin and sold it to the University of Toronto for one dollar each. (The University of Toronto still holds scans of the original assignment document, dated December 1922; the sale was formally recorded on January 1, 1923.) The line usually attached to that decision — “insulin does not belong to me, it belongs to the world” — is almost certainly apocryphal, first appearing in a 1959 children’s biography written eighteen years after Banting’s death. But the act itself is real, and it’s what matters: three scientists deliberately declined to own a thing that could keep people alive. The University then licensed it broadly to keep supply high and prices low, and insulin reached patients worldwide within a few years.
That was the ideal. A life-saving essential, deliberately un-monopolized, priced for access rather than extraction.
Here’s the part that makes “priced like insulin” a loaded phrase — and I want to name it directly rather than let it sit as an accidental double meaning. The founders’ gift did not, on its own, hold. Over the following century, three manufacturers came to control roughly 90% of the US insulin market, and the list price of a product that costs a few dollars to make climbed into the hundreds. People rationed. People died rationing. It took until 2023 — a hundred years after that one-dollar patent — for a $35 monthly cap to arrive, first for Medicare beneficiaries under the Inflation Reduction Act, then extended by Eli Lilly, Novo Nordisk, and Sanofi under sustained political pressure, who cut list prices by up to 78% almost simultaneously.
So when I say we priced Kapital like insulin, I mean it in the full, uncomfortable sense. We mean it the way insulin was supposed to be priced — the 1923 ideal. And we’re building with our eyes open about the hundred years that followed, because the cautionary tale is baked into the same word as the aspiration. An essential priced for access doesn’t stay that way by default. It stays that way by design and by governance, or it doesn’t stay that way at all.
Priced for access, governed against drift
If Kapital works the way we’ve designed it to, it has to be priced and governed the way the world learned — painfully, and twice over — that insulin has to be. Essential. Never withheld. Priced for access rather than extraction. Not a luxury good. Not a speculative asset. Infrastructure for keeping a body alive.
That’s a real constraint, not a slogan, and the obvious objection is: how do you sustain something you refuse to price for yield?
We already have the existence proof. Watch Signal. A genuinely secure, genuinely essential piece of communications infrastructure, built and scaled sustainably without extracting from its users — funded as a nonprofit, governed to stay that way, and better than most of its extractive competitors precisely because it isn’t optimizing for extraction. Signal is the answer to “that’s naive.” It isn’t naive. It’s a different design target. You can build essential infrastructure that sustains itself without turning its users into the product — but only if you decide that’s what you’re building before the incentives decide for you.
That’s the harder half of the insulin lesson. The 1923 gift wasn’t enough. The governance around it — who holds the patent, who sets the price, who’s accountable when it drifts — is what actually determines whether an essential stays accessible. So we’re not just pricing Kapital like insulin. We’re trying to govern it against the century that happened to insulin afterward.
A bigger patient
Automated finance models extract from the periphery by default. It’s not malice; it’s the metabolism. Capital pools where capital already is, and the algorithms optimize the pooling. Standing up something that runs the other way — that moves capital out to the cells, and is structurally prevented from clawing it back — means standing against that default on purpose, and building the governance to keep standing there.
I never really left medicine. I just got a bigger patient.